Developer docs
API playgroundTry for free, no card

Search company profiles

Shattuck Labs

Full company profile

uuid00023fl

Namestring
Shattuck Labs
Legal namestring
Shattuck Labs, Inc.
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Shattuck Labs, Inc. is a clinical-stage biotechnology company founded in 2016 and headquartered in Austin, Texas, with R&D operations in Durham, North Carolina. The company develops biologic medicines that target the TL1A/DR3 signaling axis for the treatment of inflammatory bowel disease (IBD) and other immune-mediated diseases, having pivoted from an earlier oncology focus. Its lead asset, SL-325, is described as the first DR3 blocking antibody to enter human clinical trials, engineered with picomolar binding affinity, high epitope specificity (avoiding cross-binding to decoy receptor 3), Fc-silencing to minimize immune complex formation and anti-drug antibody (ADA) development, and durable receptor occupancy exceeding three months. The pipeline also includes SL-425, an extended half-life variant of SL-325, and SL-846, a DR3 x IL-23R bispecific antibody combining DR3 blockade with IL-23 receptor inhibition in a single half-life extended format; both are in IND-enabling stages.

SL-325 has completed Phase 1 enrollment of 72 healthy volunteers with reported 3.7% ADA development, complete DR3 receptor occupancy at doses of 0.1 mg/kg and above, and no serious treatment-emergent adverse events across all dose levels. The company plans to initiate the Phase 2b RECEPTIVE-CD1 trial in Crohn's disease (planned enrollment ~174 patients) across U.S., Canadian, and European sites in Q3 2026, with later-stage trials expected to expand into ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and hidradenitis suppurativa.

Shattuck is publicly traded on NASDAQ under the ticker STTK (IPO completed 2020) and is pre-revenue, generating no commercial product sales. Its business model is one of clinical development with future revenue contingent on regulatory approval and commercialization of its drug candidates, planned for distribution through standard pharmaceutical wholesale channels targeting gastroenterologists and inflammatory disease specialists. As of Q1 2026, the company reported $90.4 million in cash and investments (versus $78.1 million as of December 31, 2025), a Q1 2026 net loss of $14.8 million, and a full-year 2025 net loss of $48.8 million. Recent financing activity includes a $103 million OrbiMed-led private placement (August 2025), a $50 million public offering (December 2023), and a $75 million public offering (June 2026), with stated cash runway extending into 2029.

Short descriptiontext

Shattuck Labs is a clinical-stage biotechnology company developing first-in-class DR3 blocking antibodies that target the TL1A/DR3 pathway for treating inflammatory bowel disease and other autoimmune conditions, with lead candidate SL-325 advancing through Phase 1/2 clinical trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
inflammatory bowel disease therapeutics, monoclonal antibody development, DR3 blocking antibodies, biologic medicines pipeline, clinical-stage biotechnology
Industry3 codes
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biologic Therapeutics for Inflammatory and Immune-Mediated Diseases
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical development
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company. Revenue will be generated from commercialization of drug candidates upon regulatory approval. Currently advancing SL-325 through clinical trials for inflammatory bowel disease.

biospace.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Others, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Shattuck Labs develops monoclonal antibody therapies that block the DR3 receptor to inhibit TL1A-driven inflammation, with lead candidate SL-325 advancing through Phase 1/2 clinical trials for inflammatory bowel disease (Crohn's disease and ulcerative colitis). Its pipeline also includes SL-425 (half-life extended DR3 blocker, IND-enabling) and SL-846 (DR3 x IL-23R bispecific antibody, IND-enabling). All candidates are investigational and the company is pre-revenue.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Only 3.7% of subjects developed antidrug antibodies in Phase 1 trial
+3 more records
Product overview1 text field

Shattuck Labs is a clinical-stage biotechnology company developing a pipeline of novel biologic therapies designed to block the TL1A/DR3 pathway. The company's lead program is SL-325, a first-in-class DR3 blocking antibody currently in Phase 1 clinical trials for inflammatory bowel disease (IBD). Additional pipeline programs include SL-425 (half-life extended version of SL-325) and SL-846 (DR3 x IL-23R bispecific antibody), both in IND-enabling stages. The company's approach focuses on receptor blockade of DR3, which they believe may deliver superior efficacy compared to targeting the TL1A ligand, with potentially reduced immunogenicity due to avoiding immune complex formation.

Product and service3 records
1SL-325
CategoryBiologic Therapeutic / Monoclonal Antibody
Description

SL-325 is a first-in-class DR3 blocking monoclonal antibody targeting the TL1A/DR3 pathway for the treatment of inflammatory bowel disease (IBD) and other inflammatory/immune-mediated diseases. It is engineered with picomolar binding affinity to DR3, epitope specificity that does not cross-bind to decoy receptor 3 (DcR3), Fc-silencing to prevent unwanted immune activation, and no DR3 internalization enabling durable receptor occupancy exceeding three months. Phase 1 data demonstrated only 3.7% anti-drug antibody development versus reportedly 100% for some TL1A-directed bispecifics. Intended for moderate-to-severe Crohn's disease and ulcerative colitis patients who have failed existing therapies.

2SL-425
CategoryBiologic Therapeutic / Monoclonal Antibody
Description

SL-425 is a half-life extended version of SL-325 (DR3 blocking antibody). Shattuck may select to advance SL-325 and/or SL-425 in future studies based on pharmacokinetic and pharmacodynamic properties, with each antibody offering potentially different advantages in distinct diseases and administration regimens. Currently in IND-enabling stage with indications to be determined.

3SL-846 (DR3 x IL-23R bispecific antibody)
CategoryBiologic Therapeutic / Bispecific Antibody
Description

SL-846 is a potentially first-in-class DR3 x IL-23 receptor blocking bispecific antibody that pairs DR3 blockade with IL-23R inhibition in a single, half-life extended bispecific antibody format. The dual-targeting design targets improved efficacy over monotherapy approaches for inflammatory bowel diseases and inflammatory skin diseases. Currently in IND-enabling stage with indications to be determined.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeBroad incumbent
Description

AbbVie markets Humira, Skyrizi, and Rinvoq for IBD and dominates the inflammatory bowel disease market. As the incumbent franchise leader, it competes with Shattuck for the same moderate-to-severe Crohn's and ulcerative colitis patients.

TypeBroad incumbent
Description

Eli Lilly acquired Morphic Therapeutic for ~$3.2B in 2024 to access MORF-057, an oral α4β7 inhibitor for IBD. Lilly is a broad incumbent in immunology with multiple Phase 3 IBD programs and competes with Shattuck in the inflammatory bowel disease market.

TypeDirect peer
Description

Merck is developing tulisokibart (MK-7240), an anti-TL1A monoclonal antibody acquired via the $10.8B Prometheus Biosciences deal, currently in Phase 3 for IBD. It is the most clinically advanced direct competitor to Shattuck's SL-325 in the same inflammatory bowel disease indication.

TypeBroad incumbent
Description

Johnson & Johnson markets Stelara and Tremfya for IBD, two of the leading IL-23 pathway biologics. It is a broad incumbent competing with Shattuck for moderate-to-severe Crohn's disease and ulcerative colitis patients.

TypeBroad incumbent
Description

Pfizer acquired Arena Pharmaceuticals and markets etrasimod (Velsipity) for ulcerative colitis. Pfizer is a broad incumbent with multiple IBD and immunology assets competing with Shattuck's SL-325 in moderate-to-severe IBD.

6Bristol-Myers Squibb
TypeEmerging player
Description

Bristol-Myers Squibb markets Zeposia (ozanimod), an oral S1P receptor modulator approved for ulcerative colitis. It is an emerging competitor in the IBD space alongside Shattuck's biologic SL-325, particularly competing for patients seeking oral alternatives.

7Morphic Therapeutic
TypeOthers
Description

Morphic was a clinical-stage biotech developing MORF-057, an oral α4β7 integrin inhibitor for IBD, acquired by Eli Lilly in 2024 for ~$3.2B. It serves as a relevant transaction precedent for valuation and as a former direct peer in the IBD clinical-stage biotech category.

TypeDirect peer
Description

Sanofi is developing amlitelimab, an anti-TL1A monoclonal antibody in late-stage clinical trials for IBD and other inflammatory diseases. Sanofi competes directly with Shattuck in targeting the TL1A/DR3 axis for IBD and atopic dermatitis indications.

TypeDirect peer
Description

Takeda acquired Maverix Therapeutics and is developing a TL1A-directed antibody for IBD, putting it in direct competition with Shattuck in the same molecular pathway and indication. Takeda's larger commercial footprint in gastroenterology makes it a significant competitor.

TypeDirect peer
Description

Roche is developing an anti-TL1A antibody (RG6631) for inflammatory bowel disease and other immune-mediated conditions. It competes directly with Shattuck in the TL1A/DR3 pathway for IBD with substantially greater resources and commercial reach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Shattuck Labs

Biologic Therapeutics for Inflammatory and Immune-Mediated Diseasesshattucklabs.com

Shattuck Labs is a clinical-stage biotechnology company developing first-in-class DR3 blocking antibodies that target the TL1A/DR3 pathway for treating inflammatory bowel disease and other autoimmune conditions, with lead candidate SL-325 advancing through Phase 1/2 clinical trials.

What Shattuck Labs does

Shattuck Labs, Inc. is a clinical-stage biotechnology company founded in 2016 and headquartered in Austin, Texas, with R&D operations in Durham, North Carolina. The company develops biologic medicines that target the TL1A/DR3 signaling axis for the treatment of inflammatory bowel disease (IBD) and other immune-mediated diseases, having pivoted from an earlier oncology focus. Its lead asset, SL-325, is described as the first DR3 blocking antibody to enter human clinical trials, engineered with picomolar binding affinity, high epitope specificity (avoiding cross-binding to decoy receptor 3), Fc-silencing to minimize immune complex formation and anti-drug antibody (ADA) development, and durable receptor occupancy exceeding three months. The pipeline also includes SL-425, an extended half-life variant of SL-325, and SL-846, a DR3 x IL-23R bispecific antibody combining DR3 blockade with IL-23 receptor inhibition in a single half-life extended format; both are in IND-enabling stages.

SL-325 has completed Phase 1 enrollment of 72 healthy volunteers with reported 3.7% ADA development, complete DR3 receptor occupancy at doses of 0.1 mg/kg and above, and no serious treatment-emergent adverse events across all dose levels. The company plans to initiate the Phase 2b RECEPTIVE-CD1 trial in Crohn's disease (planned enrollment ~174 patients) across U.S., Canadian, and European sites in Q3 2026, with later-stage trials expected to expand into ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and hidradenitis suppurativa.

Shattuck is publicly traded on NASDAQ under the ticker STTK (IPO completed 2020) and is pre-revenue, generating no commercial product sales. Its business model is one of clinical development with future revenue contingent on regulatory approval and commercialization of its drug candidates, planned for distribution through standard pharmaceutical wholesale channels targeting gastroenterologists and inflammatory disease specialists. As of Q1 2026, the company reported $90.4 million in cash and investments (versus $78.1 million as of December 31, 2025), a Q1 2026 net loss of $14.8 million, and a full-year 2025 net loss of $48.8 million. Recent financing activity includes a $103 million OrbiMed-led private placement (August 2025), a $50 million public offering (December 2023), and a $75 million public offering (June 2026), with stated cash runway extending into 2029.

Shattuck Labs firmographics

Firmographics
Name
Shattuck Labs
Legal name
Shattuck Labs, Inc.
Website
https://shattucklabs.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
Shattuck Labs is a clinical-stage biotechnology company developing first-in-class DR3 blocking antibodies that target the TL1A/DR3 pathway for treating inflammatory bowel disease and other autoimmune conditions, with lead candidate SL-325 advancing through Phase 1/2 clinical trials.
Ownership category
akta.pro rank

Shattuck Labs industry classification

Industry
Product category
Biologic Therapeutics for Inflammatory and Immune-Mediated Diseases
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Inflammatory bowel disease therapeutics
  • Monoclonal antibody development
  • DR3 blocking antibodies
  • Biologic medicines pipeline
  • Clinical-stage biotechnology

Where Shattuck Labs is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Shattuck Labs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others, Marketing or Sales

Revenue model

  1. Biopharmaceutical development: Pre-revenue clinical-stage biotech company. Revenue will be generated from commercialization of drug candidates upon regulatory approval. Currently advancing SL-325 through clinical trials for inflammatory bowel disease.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Shattuck Labs product offering

Product offering

Core offering

Shattuck Labs develops monoclonal antibody therapies that block the DR3 receptor to inhibit TL1A-driven inflammation, with lead candidate SL-325 advancing through Phase 1/2 clinical trials for inflammatory bowel disease (Crohn's disease and ulcerative colitis). Its pipeline also includes SL-425 (half-life extended DR3 blocker, IND-enabling) and SL-846 (DR3 x IL-23R bispecific antibody, IND-enabling). All candidates are investigational and the company is pre-revenue.

Product overview

Shattuck Labs is a clinical-stage biotechnology company developing a pipeline of novel biologic therapies designed to block the TL1A/DR3 pathway. The company's lead program is SL-325, a first-in-class DR3 blocking antibody currently in Phase 1 clinical trials for inflammatory bowel disease (IBD). Additional pipeline programs include SL-425 (half-life extended version of SL-325) and SL-846 (DR3 x IL-23R bispecific antibody), both in IND-enabling stages. The company's approach focuses on receptor blockade of DR3, which they believe may deliver superior efficacy compared to targeting the TL1A ligand, with potentially reduced immunogenicity due to avoiding immune complex formation.

Differentiator

Problem solved

Functional benefit

Products and services

  • SL-325 SL-325 is a first-in-class DR3 blocking monoclonal antibody targeting the TL1A/DR3 pathway for the treatment of inflammatory bowel disease (IBD) and other inflammatory/immune-mediated diseases. It is engineered with picomolar binding affinity to DR3, epitope specificity that does not cross-bind to decoy receptor 3 (DcR3), Fc-silencing to prevent unwanted immune activation, and no DR3 internalization enabling durable receptor occupancy exceeding three months. Phase 1 data demonstrated only 3.7% anti-drug antibody development versus reportedly 100% for some TL1A-directed bispecifics. Intended for moderate-to-severe Crohn's disease and ulcerative colitis patients who have failed existing therapies.
  • SL-425 SL-425 is a half-life extended version of SL-325 (DR3 blocking antibody). Shattuck may select to advance SL-325 and/or SL-425 in future studies based on pharmacokinetic and pharmacodynamic properties, with each antibody offering potentially different advantages in distinct diseases and administration regimens. Currently in IND-enabling stage with indications to be determined.
  • SL-846 (DR3 x IL-23R bispecific antibody) SL-846 is a potentially first-in-class DR3 x IL-23 receptor blocking bispecific antibody that pairs DR3 blockade with IL-23R inhibition in a single, half-life extended bispecific antibody format. The dual-targeting design targets improved efficacy over monotherapy approaches for inflammatory bowel diseases and inflammatory skin diseases. Currently in IND-enabling stage with indications to be determined.

Quantifiable outcome

  • Only 3.7% of subjects developed antidrug antibodies in Phase 1 trial
  • +3 more outcomes

Companies that use Shattuck Labs

Customer profile

Segments2 records

Ideal customer profiles1 record

Shattuck Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Shattuck Labs partnerships and signals

Strategic signal

Scale indicators13 records

Recent moves1 record

Shattuck Labs competitors and assessment

Company assessment

Broad incumbents

  • AbbVie: AbbVie markets Humira, Skyrizi, and Rinvoq for IBD and dominates the inflammatory bowel disease market. As the incumbent franchise leader, it competes with Shattuck for the same moderate-to-severe Crohn's and ulcerative colitis patients.
  • Eli Lilly: Eli Lilly acquired Morphic Therapeutic for ~$3.2B in 2024 to access MORF-057, an oral α4β7 inhibitor for IBD. Lilly is a broad incumbent in immunology with multiple Phase 3 IBD programs and competes with Shattuck in the inflammatory bowel disease market.
  • Johnson & Johnson: Johnson & Johnson markets Stelara and Tremfya for IBD, two of the leading IL-23 pathway biologics. It is a broad incumbent competing with Shattuck for moderate-to-severe Crohn's disease and ulcerative colitis patients.
  • Pfizer: Pfizer acquired Arena Pharmaceuticals and markets etrasimod (Velsipity) for ulcerative colitis. Pfizer is a broad incumbent with multiple IBD and immunology assets competing with Shattuck's SL-325 in moderate-to-severe IBD.

Direct peers

  • Merck & Co. Merck is developing tulisokibart (MK-7240), an anti-TL1A monoclonal antibody acquired via the $10.8B Prometheus Biosciences deal, currently in Phase 3 for IBD. It is the most clinically advanced direct competitor to Shattuck's SL-325 in the same inflammatory bowel disease indication.
  • Sanofi: Sanofi is developing amlitelimab, an anti-TL1A monoclonal antibody in late-stage clinical trials for IBD and other inflammatory diseases. Sanofi competes directly with Shattuck in targeting the TL1A/DR3 axis for IBD and atopic dermatitis indications.
  • Takeda Pharmaceutical: Takeda acquired Maverix Therapeutics and is developing a TL1A-directed antibody for IBD, putting it in direct competition with Shattuck in the same molecular pathway and indication. Takeda's larger commercial footprint in gastroenterology makes it a significant competitor.
  • Roche: Roche is developing an anti-TL1A antibody (RG6631) for inflammatory bowel disease and other immune-mediated conditions. It competes directly with Shattuck in the TL1A/DR3 pathway for IBD with substantially greater resources and commercial reach.

Emerging players

  • Bristol-Myers Squibb: Bristol-Myers Squibb markets Zeposia (ozanimod), an oral S1P receptor modulator approved for ulcerative colitis. It is an emerging competitor in the IBD space alongside Shattuck's biologic SL-325, particularly competing for patients seeking oral alternatives.

Others

  • Morphic Therapeutic: Morphic was a clinical-stage biotech developing MORF-057, an oral α4β7 integrin inhibitor for IBD, acquired by Eli Lilly in 2024 for ~$3.2B. It serves as a relevant transaction precedent for valuation and as a former direct peer in the IBD clinical-stage biotech category.

Market position

Strengths5 records

Weaknesses5 records

Key risks6 records

Key highlights6 records

Customer concentration

Shattuck Labs social profiles

Digital presence

Shattuck Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Shattuck Labs leadership team

Management profile

Number of profiles

Profiles14 records

Shattuck Labs funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Shattuck Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shattuck Labs

What does Shattuck Labs do?

Shattuck Labs develops monoclonal antibody therapies that block the DR3 receptor to inhibit TL1A-driven inflammation, with lead candidate SL-325 advancing through Phase 1/2 clinical trials for inflammatory bowel disease (Crohn's disease and ulcerative colitis). Its pipeline also includes SL-425 (half-life extended DR3 blocker, IND-enabling) and SL-846 (DR3 x IL-23R bispecific antibody, IND-enabling). All candidates are investigational and the company is pre-revenue.

Is Shattuck Labs a public or private company?

Shattuck Labs is a public company. It is classified as public and is currently operating.

When was Shattuck Labs founded?

Shattuck Labs was founded in 2017. It employs 51 to 100 people.

Where is Shattuck Labs based?

Shattuck Labs is headquartered in Austin, United States, in the North America region.

How does Shattuck Labs make money?

One revenue line is on record: biopharmaceutical development.

Who are Shattuck Labs's main competitors?

Broad incumbents on record are AbbVie, Eli Lilly, Johnson & Johnson and Pfizer. Direct peers are Merck & Co., Sanofi, Takeda Pharmaceutical and Roche. Bristol-Myers Squibb is listed as an emerging player. Morphic Therapeutic is listed as an others.

Does Shattuck Labs have an API?

No public API is recorded for Shattuck Labs.

What industry is Shattuck Labs in?

Shattuck Labs's product category is Biologic Therapeutics for Inflammatory and Immune-Mediated Diseases. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialShattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Shattuck Labs granted inducement stock options to purchase 384,000 shares at $4.85 each, with a 10-year term. Vesting is 25% on the first anniversary and the remainder monthly over 36 months. The grants were approved by the Compensation Committee under Nasdaq Rule 5635(c)(4).Business & FinancialCrohn's Disease Clinical Trial Pipeline Expands As 90+ Companies Race To Redefine Crohn's Disease Treatment Landscape DelveinsightDelveInsight's report profiles 90+ companies and 90+ pipeline drugs for Crohn's disease, covering clinical and nonclinical stages. Recent updates include Shattuck Labs' Phase IIb trial initiation, AbbVie's SKYRIZI subcutaneous approval, Sanofi/Teva's positive Phase IIb results, and Eli Lilly's Omvoh data. The report also assesses products by type, stage, and route of administration.American Banking and Market NewsShattuck Labs (NASDAQ:STTK) Stock Gets Downgrade from Wall Street ZenWall Street Zen downgraded Shattuck Labs from hold to sell. The stock opened at $4.62, with an average analyst rating of Buy and a consensus target of $13.70. The company reported a quarterly loss of $0.14 per share, missing estimates.Investing.comShattuck Labs stock price target maintained at $18 by Raymond JamesRaymond James maintained its Strong Buy rating and $18 price target on Shattuck Labs, citing a 152% annual return despite a recent 10% decline. The company reported Q3 2026 results, holds more cash than debt, and plans Phase 2 studies for SL-325 in Crohn's disease and hidradenitis suppurativa.American Banking and Market NewsShattuck Labs, Inc. (NASDAQ:STTK) Stock Has Average Target Price of $13.70 According to BrokeragesShattuck Labs shares received an average "Buy" rating from 13 analysts, with a 1-year price target of $13.70. The company reported a loss of $0.12 per share for the quarter, meeting consensus, and institutional investors own 58.74% of the stock.Ticker ReportShattuck Labs (STTK) – Research Analysts’ Recent Ratings ChangesShattuck Labs received multiple analyst rating changes and price target updates, including UBS setting a $17 buy target, Wedbush raising its target to $14, and Needham raising it to $19. The company is a clinical-stage biotech developing immunotherapies for cancer using its ARC platform.MarketBeatShattuck Labs, Inc. $STTK Stock Purchased by Pinnacle Associates Ltd.Pinnacle Associates Ltd. increased its stake in Shattuck Labs by 12.2% in Q3, buying 228,337 shares to own 2,099,779 shares worth $14.32 million. Analysts rate the stock a Buy with an average price target of $13.70, while the company reported a loss of $0.12 per share for the quarter.MarketBeatShattuck Labs, Inc. (NASDAQ:STTK) Stock Has Consensus Price Target of $13.70Shattuck Labs has a consensus Buy rating from 13 analysts, with an average price target of $13.70. The stock opened at $5.37, and analysts predict a fiscal-year loss of $0.45 per share. Institutional investors hold 58.74% of the stock.Ticker ReportShattuck Labs, Inc. (NASDAQ:STTK) Sees Large Growth in Short InterestShattuck Labs saw short interest rise 60.8% to 10.95 million shares as of September 30, with 12% of shares short sold. Analysts rate the stock a Buy with a consensus target of $13.70, while institutional investors hold 58.74% of shares.MarketBeatShattuck Labs, Inc. (NASDAQ:STTK) Sees Large Growth in Short InterestShattuck Labs saw short interest rise 60.8% to 10,947,042 shares as of September 30th. Analysts have an average Buy rating with a $13.70 target price, and institutional ownership stands at 58.74%.